Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Obesity

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 78 articles: HTML format

Single Articles

September 2025
1. WHARTON S, Lingvay I, Bogdanski P, Duque do Vale R, et al
   Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
   N Engl J Med. 2025;393:1077-1087.
   PubMed     Abstract available
   
   
   
2. WHARTON S, Aronne LJ, Stefanski A, Alfaris NF, et al
   Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
   N Engl J Med. 2025 Sep 16. doi: 10.1056/NEJMoa2511774.
   PubMed     Abstract available
   
   
   
3. JI L, Qian L
   Once-Weekly Mazdutide in Obesity or Overweight. Reply.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   
4. ZHANG Y, Yu L, Liu ZT
   Once-Weekly Mazdutide in Obesity or Overweight.
   N Engl J Med. 2025;393:10.
   PubMed    
   
   
   August 2025
5. KOTANIDIS CP, Lincoff AM, Shikora SA
   Managing Obesity.
   N Engl J Med. 2025;393:719-721.
   PubMed    
   
   
   
6. HALES CM
   Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care.
   N Engl J Med. 2025;393:712-714.
   PubMed    
   
   
   July 2025
7. GREENWAY FL
   Semaglutide and Tirzepatide to Treat Obesity.
   N Engl J Med. 2025;393:84-85.
   PubMed    
   
   
   June 2025
8. JASTREBOFF AM, Bunck MC, Ahmad NN
   Tirzepatide for Obesity Treatment and Diabetes Prevention. Reply.
   N Engl J Med. 2025;392:2492-2493.
   PubMed    
   
   
   
9. SHUKLA AK, Bhavya B
   Tirzepatide for Obesity Treatment and Diabetes Prevention.
   N Engl J Med. 2025;392:2492.
   PubMed    
   
   
   
10. BIRKENFELD AL, Bergman M, Stefan N
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2025;392:2491-2492.
    PubMed    
    
    
    
11. JASTREBOFF AM, Ryan DH, Bays HE, Ebeling PR, et al
    Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial.
    N Engl J Med. 2025 Jun 23. doi: 10.1056/NEJMoa2504214.
    PubMed     Abstract available
    
    
    
12. GARVEY WT, Bluher M, Osorto Contreras CK, Davies MJ, et al
    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502081.
    PubMed     Abstract available
    
    
    
13. DAVIES MJ, Bajaj HS, Broholm C, Eliasen A, et al
    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
    N Engl J Med. 2025 Jun 22. doi: 10.1056/NEJMoa2502082.
    PubMed     Abstract available
    
    
    May 2025
14. JI L, Jiang H, Bi Y, Li H, et al
    Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMoa2411528.
    PubMed     Abstract available
    
    
    
15. ARODA VR, Perreault L
    Overweight and Obesity - Capturing the Whole Picture.
    N Engl J Med. 2025 May 25. doi: 10.1056/NEJMe2505819.
    PubMed    
    
    
    
16. ARONNE LJ, Horn DB, le Roux CW, Ho W, et al
    Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
    N Engl J Med. 2025 May 11. doi: 10.1056/NEJMoa2416394.
    PubMed     Abstract available
    
    
    
17. FOX CK, Harder-Lauridsen NM, Arslanian S
    Liraglutide for Children 6 to <12 Years of Age with Obesity. Reply.
    N Engl J Med. 2025;392:1868.
    PubMed    
    
    
    
18. EGAN JM, Kapogiannis D
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1868.
    PubMed    
    
    
    
19. JI C, Wang M
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1867.
    PubMed    
    
    
    
20. MALOZOWSKI S
    Liraglutide for Children 6 to <12 Years of Age with Obesity.
    N Engl J Med. 2025;392:1866-1867.
    PubMed    
    
    
    April 2025
21. PACKER M, Kramer CM, Borlaug BA
    Tirzepatide for Heart Failure and Obesity. Reply.
    N Engl J Med. 2025;392:1661-1662.
    PubMed    
    
    
    
22. ALI MK
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1661.
    PubMed    
    
    
    
23. MARINE JE, Mandrola J, Prasad V
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
24. KRAKAUER JC, Krakauer NY
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1660.
    PubMed    
    
    
    
25. WAGNER J
    Tirzepatide for Heart Failure and Obesity.
    N Engl J Med. 2025;392:1659-1660.
    PubMed    
    
    
    March 2025
26. MAGNUSSEN C, Alegre-Diaz J, Al-Nasser LA, Amouyel P, et al
    Global Effect of Cardiovascular Risk Factors on Lifetime Estimates.
    N Engl J Med. 2025 Mar 30. doi: 10.1056/NEJMoa2415879.
    PubMed     Abstract available
    
    
    November 2024
27. PACKER M, Zile MR, Kramer CM, Baum SJ, et al
    Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMoa2410027.
    PubMed     Abstract available
    
    
    
28. RUBIN EJ, Leopold J, Morrissey S
    NEJM at AHA - Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2024 Nov 16. doi: 10.1056/NEJMe2414470.
    PubMed    
    
    
    
29. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    October 2024
30. BLIDDAL H, Bays H, Czernichow S, Udden Hemmingsson J, et al
    Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
    N Engl J Med. 2024;391:1573-1583.
    PubMed     Abstract available
    
    
    
31. 
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024;391:1464.
    PubMed    
    
    
    September 2024
32. DRUCKER DJ
    Discovery of GLP-1-Based Drugs for the Treatment of Obesity.
    N Engl J Med. 2024 Sep 19. doi: 10.1056/NEJMcibr2409089.
    PubMed    
    
    
    
33. BARRETT T, Hamilton-Shield J
    Childhood Obesity and GLP-1 Receptor Agonists - A Coming of Age?
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMe2410560.
    PubMed    
    
    
    
34. FOX CK, Barrientos-Perez M, Bomberg EM, Dcruz J, et al
    Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial.
    N Engl J Med. 2024 Sep 10. doi: 10.1056/NEJMoa2407379.
    PubMed     Abstract available
    
    
    July 2024
35. KOSIBOROD MN, Petrie MC, Borlaug BA
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
    N Engl J Med. 2024;391:381-382.
    PubMed    
    
    
    
36. AMMON JP, Jackson CD
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:381.
    PubMed    
    
    
    
37. WAGNER J
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380-381.
    PubMed    
    
    
    
38. COHEN C, Cohen R, Sabouret P
    Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes.
    N Engl J Med. 2024;391:380.
    PubMed    
    
    
    June 2024
39. MALHOTRA A, Grunstein RR, Fietze I, Weaver TE, et al
    Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
    N Engl J Med. 2024 Jun 21. doi: 10.1056/NEJMoa2404881.
    PubMed     Abstract available
    
    
    
40. 
    Treating Obesity in Kids: ITT Episode 31.
    N Engl J Med. 2024;390:e52.
    PubMed    
    
    
    May 2024
41. EMANUEL EJ, Dellgren JL, McCoy MS, Persad G, et al
    Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    N Engl J Med. 2024;390:1839-1842.
    PubMed    
    
    
    
42. EGAN JM
    Physiological Integration of Taste and Metabolism.
    N Engl J Med. 2024;390:1699-1710.
    PubMed    
    
    
    April 2024
43. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    PubMed     Abstract available
    
    
    February 2024
44. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    
    
    
    
45. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    
    
    
    
46. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
47. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    
    
    
    
48. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    
    
    
    
49. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    
    
    
    
50. GORTMAKER SL, Bleich SN, Williams DR
    Childhood Obesity Prevention - Focusing on Population-Level Interventions and Equity.
    N Engl J Med. 2024;390:681-683.
    PubMed    
    
    
    
51. GOLOVATY I, Hagan S
    Direct-to-Consumer Platforms for New Antiobesity Medications - Concerns and Potential Opportunities.
    N Engl J Med. 2024;390:677-680.
    PubMed    
    
    
    December 2023
52. KOSIBOROD MN, Borlaug BA, Petrie MC
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity. Reply.
    N Engl J Med. 2023;389:2398-2399.
    PubMed    
    
    
    
53. O'DOWLING R
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
54. WAGNER J
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2398.
    PubMed    
    
    
    
55. GAO Y, Gao Y, Qiu H
    Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023;389:2397-2398.
    PubMed    
    
    
    
56. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    
    
    
    
57. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    
    
    
    
58. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    
    
    
    November 2023
59. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available
    
    
    
60. KHERA A, Powell-Wiley TM
    SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMe2312646.
    PubMed    
    
    
    October 2023
61. JASTREBOFF AM, Kaplan LM, Hartman ML
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.
    N Engl J Med. 2023;389:1629-1630.
    PubMed    
    
    
    
62. ELFEKI MA, Alkhouri N
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1629.
    PubMed    
    
    
    
63. BISSON A, Fauchier G, Fauchier L
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity.
    N Engl J Med. 2023;389:1628.
    PubMed    
    
    
    
64. HANNON TS, Arslanian SA
    Obesity in Adolescents. Reply.
    N Engl J Med. 2023;389:1344.
    PubMed    
    
    
    
65. BHOWMIK S, Mahapatra HS
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343-1344.
    PubMed    
    
    
    
66. ABU DAYYEH B, Stier C
    Obesity in Adolescents.
    N Engl J Med. 2023;389:1343.
    PubMed    
    
    
    August 2023
67. 
    Obesity and Heart Failure.
    N Engl J Med. 2023;389:e15.
    PubMed    
    
    
    
68. KOSIBOROD MN, Abildstrom SZ, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
    N Engl J Med. 2023 Aug 25. doi: 10.1056/NEJMoa2306963.
    PubMed     Abstract available
    
    
    
69. PATTI ME
    Triple G Agonists - A Home Run for Obesity?
    N Engl J Med. 2023;389:562-563.
    PubMed    
    
    
    July 2023
70. HANNON TS, Arslanian SA
    Obesity in Adolescents.
    N Engl J Med. 2023;389:251-261.
    PubMed    
    
    
    June 2023
71. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available
    
    
    
72. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available
    
    
    
73. STOOPS H, Dar M
    Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
    N Engl J Med. 2023;388:2309-2311.
    PubMed    
    
    
    
74. ROSEN CJ
    Antagonizing the Leptin Receptor in Obesity.
    N Engl J Med. 2023;388:2291-2293.
    PubMed    
    
    
    
75. FUNCKE JB, Moepps B, Roos J, von Schnurbein J, et al
    Rare Antagonistic Leptin Variants and Severe, Early-Onset Obesity.
    N Engl J Med. 2023;388:2253-2261.
    PubMed     Abstract available
    
    
    March 2023
76. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    
    
    
    
77. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    
    
    
    
78. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.